Skip to main content
Fig. 1 | Cancer Nanotechnology

Fig. 1

From: Targeting BMI-1 with PLGA–PEG nanoparticle-containing PTC209 modulates the behavior of human glioblastoma stem cells and cancer cells

Fig. 1

A schematic overview of experimental design. PTC209, a potent and selective BMI-1 inhibitor, was loaded into the PLGA–PEG nanoparticle conjugated with CD133 monoclonal antibodies. The size of nanoparticles was measured by transmission electron microscopy (TEM). TEM images showed particles had an average size of ~ 75 nm. Antitumor effects of the Nano-PTC209 on the proliferation, viability, and migration/invasion of glioblastoma stem-like cells (GSCs) and the human glioblastoma cell line (U87) were assessed

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us